Junfang Ji, Xin Zheng, Marshonna Forgues, Taro Yamashita, Eliane L. Wauthier, Lola M. Reid, Xinyu Wen, Young Song, Jun S. Wei, Javed Khan, Snorri S. Thorgeirsson, Xin Wei Wang – 8 May 2015 – Therapies that target cancer stem cells (CSCs) hold promise in eliminating cancer burden. However, normal stem cells are likely to be targeted owing to their similarities to CSCs. It is established that epithelial cell adhesion molecule (EpCAM) is a biomarker for normal hepatic stem cells (HpSCs), and EpCAM+AFP+ hepatocellular carcinoma (HCC) cells have enriched hepatic CSCs.

Andri Lederer, Pia Herrmann, Daniel Seehofer, Manfred Dietel, Johann Pratschke, Peter Schlag, Ulrike Stein – 8 May 2015 – Curative treatment of intrahepatic cholangiocarcinoma (ICC) and hilar cholangiocarcinoma (Klatskin tumors) is limited to surgical resection or orthotopic liver transplantation. However, not all patients benefit from a surgical approach and suffer from early tumor recurrence. Response to chemotherapy is generally poor and, until today, no targeted therapy could be established.

Chao Dong, Shifang Peng – 7 May 2015

Poonam Mishra, Jeffrey Murray, Debra Birnkrant – 7 May 2015 – Therapeutic options for treatment of chronic hepatitis C have improved substantially since the approval of direct‐acting antiviral agents (DAAs). Several interferon (IFN)‐free or IFN‐ and ribavirin (RBV)‐free treatment regimens with shorter durations and improved efficacy and safety profiles are now available. The U.S.

Wiley Barton, Fergus Shanahan, Paul D. Cotter, Orla O'Sullivan – 7 May 2015 – Watch a video presentation of this article

Eric F. Martin, Christopher O'Brien – 7 May 2015 – Watch a video presentation of this article

Poonam Mishra, Jeffrey Murray, Debra Birnkrant – 7 May 2015 – Therapeutic options for treatment of chronic hepatitis C have improved substantially since the approval of direct‐acting antiviral agents (DAAs). Several interferon (IFN)‐free or IFN‐ and ribavirin (RBV)‐free treatment regimens with shorter durations and improved efficacy and safety profiles are now available. The U.S.

Poonam Mishra, Jeffrey Murray, Debra Birnkrant – 7 May 2015 – Therapeutic options for treatment of chronic hepatitis C have improved substantially since the approval of direct‐acting antiviral agents (DAAs). Several interferon (IFN)‐free or IFN‐ and ribavirin (RBV)‐free treatment regimens with shorter durations and improved efficacy and safety profiles are now available. The U.S.

Anitha Yadav, Hugo E. Vargas – 7 May 2015 – Watch a video presentation of this article

Eamonn M.M. Quigley – 7 May 2015 – Watch a video presentation of this article